全球子宫内膜异位症药物市场规模（按产品、应用、地区、范围和预测）

子宫内膜异位症药物市场规模及预测

近年来子宫内膜异位症药物的市场规模一直以显着的速度快速增长，预计2021年至2028年的市场规模、估计和预测中该市场将出现大幅增长。

子宫内膜异位症盛行率的不断上升也提高了女性对子宫内膜异位症治疗的认识。此外，子宫内膜异位症发生率的显着增加和研发投入也为该市场创造了进一步的成长机会。全球子宫内膜异位症药物市场报告对市场进行了全面的评估。它对关键细分市场、趋势、市场推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

全球子宫内膜异位症药物市场的定义

子宫内膜异位症是一种慢性、疼痛的疾病，其中子宫周围的组织（存在于输卵管、卵巢和支撑子宫的韧带中）破裂，引起发炎和内出血。这会导致不孕、沾黏、疼痛、疤痕组织形成和肠道问题。此病的症状包括月经期间排便疼痛，性交疼痛，月经前和月经期间疼痛，不孕，月经期间排尿疼痛，疲劳以及腹泻，噁心和便秘等胃肠道问题。由于子宫内膜异位症是一种终身疾病，因此根据疾病的程度、疼痛程度和生育能力製定医疗管理策略非常重要。

多种药物可用于治疗子宫内膜异位症，包括止痛药、荷尔蒙避孕药、仅含孕酮的避孕药、促性腺激素释放激素 (GnRH) 类似物和芳香酶抑制剂。芳香化酶是一种能增加体内雌激素产生的化学物质。芳香化酶抑制剂可以阻止这一过程，从而降低雌激素水平。这些药物不常规用于治疗子宫内膜异位症。另一方面，荷尔蒙避孕药可以阻止通常伴随子宫内膜异位症出现的月经过多。

全球子宫内膜异位症药物市场概况

对女性健康日益增长的兴趣是预测期内推动子宫内膜异位症药物市场规模成长的关键因素。各政府部门和组织正在努力提高人们的意识，以克服无知和缺乏教育带来的课题。对女性健康的关注将导致全球子宫内膜异位症药物市场的扩大。此外，该疾病的发生率正在显着增加，预计研发投资将积极推动全球子宫内膜异位症药物市场的成长。

市场面临某些限制和课题，阻碍了整体成长。例如，子宫内膜异位症药物市场以高成本的荷尔蒙治疗为主，这是患者主要关心的问题，预计在预测期内将减缓市场成长。此外，对于子宫内膜异位症和子宫内膜癌等各种妇科癌症适应症的认知不足，对市场成长构成了课题。此外，诊断该疾病所需的时间很长，研究人员估计需要七到九年。目前，由于缺乏医疗基础设施和高科技医疗设备和器械，无法进行非侵入性诊断测试。这些都是阻碍全球子宫内膜异位症药物市场整体成长的潜在因素。

目录

第 1 章全球子宫内膜异位症药物市场：简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 第一次面试
• 资料来源列表

第 4 章：全球子宫内膜异位症药物市场展望

• 概述
• 市场动态
• 驱动程式
• 阻碍因素
• 机会
• 波特五力模型
• 价值链分析

第 5 章全球子宫内膜异位症药物市场（按产品划分）

• 荷尔蒙疗法
• 添加药物
• 孕酮
• 中草药

第6章 全球子宫内膜异位症药物市场（依应用）

• 医院
• 诊所
• 研究机构

第7章全球子宫内膜异位症药物市场（按地区）

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 德国
• 英国
• 法国
• 其他欧洲国家 亚太地区
• 中国
• 日本
• 印度
• 其他亚太地区
• 世界其他地区
• 拉丁美洲
• 中东和非洲

第 8 章：全球子宫内膜异位症药物市场：竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第9章 公司简介

• AbbVie
• Astellas Pharma
• AstraZeneca
• Debiopharm Group
• Evotec AG
• Kissei Pharmaceutical
• Neurocrine Biosciences
• ObsEva
• Pfizer
• Repros Therapeutics
• Roivant Sciences GmbH
• Takeda Pharmaceutical Company Limited
• ValiRx

第10章 附录

• 关联调查

Endometriosis Drugs Market Size And Forecast

Endometriosis Drugs Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

The growing prevalence of endometriosis has also lead to higher awareness among women related to endometriosis treatment. Moreover, the significant rise in the occurrence of this disease, investment in research, and development are also increasingly expanding growth opportunities in this market. The Global Endometriosis Drugs Market report provides a holistic evaluation of the market. The report offers comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Endometriosis Drugs Market Definition

Endometriosis is a chronic and painful condition, where the tissues that outline the uterus externally (found in the fallopian tubes, ovaries, and ligaments that support the uterus) ruptures and causes inflammation and internal bleeding. This can cause infertility, adhesions, pain, scar tissue formation, and bowel problems. Symptoms of the disease include painful bowel movements during periods, pain with sex, pain before and during periods, infertility, painful urination during periods, fatigue, and other gastrointestinal problems such as diarrhea, nausea, and constipation. Endometriosis is a lifelong condition so it is important to develop a medical strategy to manage it based on the extent of the disease, severity of pain, and potential plans for pregnancy.

There are various medications available to cure endometriosis such as Pain Medication, Hormone Birth Control, Progestin-only contraceptives, Gonadotroin-releasing Hormone (GnRH) Analogues, and Aromatase Inhibitors. Aromatase is a chemical that boosts your body's estrogen production. Aromatase inhibitors block it, which lowers your estrogen level. These medicines aren't routinely used to treat endometriosis. Whereas, hormone birth control can stop the heavy menstrual bleeding that generally accompanies endometriosis.

Global Endometriosis Drugs Market Overview

The growing focus emphasis on women's health is the key factor in boosting the growth of the endometriosis drugs market size during the forecast period. The various governmental authorities and organizations are working to raise awareness to overcome unawareness and uneducated challenges problems. The focus on women's health will lead to the expansion of the global endometriosis drugs market. Moreover, the significant rise in the occurrence of this disease, investment in research, and development has positively anticipated in propelling the growth of the global Endometriosis drugs market.

There are certain restraints and challenges faced which will hinder the overall market growth. The factors such as the endometriosis drug market are dominated by high-cost hormone-based therapeutics, which is a significant concern for patients and is estimated to sluggish growth during the forecast period. Lack of awareness about various gynecological cancer indications such as endometriosis and endometrial cancer was a challenge for the growth of the market. Further, the time that is taken to diagnose the disease is high, which is estimated by the researchers as seven to nine years. Till now, there are no diagnostic tests available that are non-invasive coupled with a lack of medical infrastructure and hi-tech medical equipment and devices. These are the potential restraints hampering the overall growth of the global Endometriosis drugs market.

Global Endometriosis Drugs Market: Segmentation Analysis

Global Endometriosis Drugs Market is segmented based on Product, Application, And Geography.

Endometriosis Drugs Market by Product

• Hormonal Therapy
• Add-back Medication
• Progestogens
• Chinese Herbs

Based on Product, the market is bifurcated into Hormonal Therapy, Add-back Medication, Progestogens, and Chinese Herbs. The hormone therapy segment holds the largest market share for the forecast period. It is considered the most effective treatment for endometriosis as it can reduce or effectively eliminate the pain associated with the condition compared with analgesics. This factor will increase sales of medications that act on hormones associated with the condition. The sales of hormonal medications will further improve with the introduction of novel drug delivery systems.

Endometriosis Drugs Market by Application

• Hospitals
• Clinics
• Research Institutes

Based on Application, the market is bifurcated into Hospitals, Clinics, Research Institutes. The hospital segment is estimated to witness the highest CAGR for the forecast period. The factors that can be attributed to the growing prevalence of endometriosis and rise in the occurrence of this disease are fueling the demand for this segment.

Endometriosis Drugs Market by Geography

On the basis of regional analysis, the Global Endometriosis Drugs Market is classified into

North America

Europe

Asia Pacific

Rest of the world

North America holds the largest market share. The increasing treatment costs, higher disability losses, and the large number of reproductive populations that are suffering from endometriosis. High awareness among people, strong governmental initiatives and ongoing projects will boost the market in this region.

Key Players

The market analysis entails a section solely dedicated to major players in the Global Endometriosis Drugs Market wherein our analysts provide an insight into the financial statements of all the major players along with its key developments product benchmarking and SWOT analysis. The company profile section also includes a business overview and financial information. The companies that are provided in this section can be customized according to the client's requirements.

• AbbVie
• Astellas Pharma
• AstraZeneca
• Debiopharm Group
• Evotec AG
• Kissei Pharmaceutical
• Neurocrine Biosciences
• ObsEva
• Pfizer
• Repros Therapeutics
• Roivant Sciences GmbH
• Takeda Pharmaceutical Company Limited
• ValiRx

Key Developments

Partnerships, Collaborations and Agreements

• The US Food and Medication Administration (FDA) granted AbbVie Inc. approval for their drug ORILISS in July 2018. (elagolix). This is a GnRH-type medication that is used to relieve endometriosis pain that is severe to moderate.
• In July 2017, Evotec AG reported that a programme from their multi-target endometriosis alliance with Bayer had moved into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
• In January 2021, Myovant Sciences and Pfizer Inc. announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis found clinically significant reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over a year.

Product Launches and Product Expansions

• In October 2018, Astellas Pharma Inc. reported that building and remodelling of new facilities for the research, development, and manufacture of novel pharmaceuticals employing new Modality/Technology had commenced in Toyama and Tsukuba, Japan, as well as Massachusetts, USA.

TABLE OF CONTENTS

1. Introduction of Global Endometriosis Drugs Market

• Overview of the Market
• Scope of Report
• Assumptions

2. Executive Summary

3. Research Methodology of Verified Market Research

• Data Mining
• Validation
• Primary Interviews
• List of Data Sources

4. Global Endometriosis Drugs Market Outlook

• Overview
• Market Dynamics
• Drivers
• Restraints
• Opportunities
• Porters Five Force Model
• Value Chain Analysis

5. Global Endometriosis Drugs Market, By Product

• Hormonal Therapy
• Add-back Medication
• Progestogens
• Chinese Herbs

6. Global Endometriosis Drugs Market, By Application

• Hospitals
• Clinics
• Research Institutes

7. Global Endometriosis Drugs Market, By Geography

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific
• Rest of the World
• Latin America
• Middle East & Africa

8. Global Endometriosis Drugs Market Competitive Landscape

• Overview
• Company Market Ranking
• Key Development Strategies

9. Company Profiles

• AbbVie
• Astellas Pharma
• AstraZeneca
• Debiopharm Group
• Evotec AG
• Kissei Pharmaceutical
• Neurocrine Biosciences
• ObsEva
• Pfizer
• Repros Therapeutics
• Roivant Sciences GmbH
• Takeda Pharmaceutical Company Limited
• ValiRx

10. Appendix

• Related Reports